Ellis George LLP: CA Court of Appeal Upholds $5 Million Jury Verdict Against Bristol-Meyers-Squibb-owned Impact Biomedicines
SAN DIEGO, July 21, 2025--(BUSINESS WIRE)--Ellis George LLP announced that The California Court of Appeal, Fourth Appellate District, has reversed a trial court order that reduced a jury verdict against Impact Biomedicines and instead reinstated the original $5,020,000 award. Impact Biomedicines, a division of Bristol-Meyers-Squibb, and Impact Biomedicine's founder and owner, Dr. John Hood, must pay San Diego physician and Alzheimer's researcher James Brewer M.D., Ph.D., more than $1 million in compensatory damages and $4 million in punitive damages in a fraudulent concealment case filed in 2019.
Dr. Brewer, chair of the neurology department at UC San Diego, was represented by Christopher W. Arledge and Courtney L. Mitchell, both of Ellis George LLP, and Peter Afrasiabi of One LLP.
At trial in the San Diego County Superior Court, a 12-member jury awarded Dr. Brewer more than $5 million, finding that Impact Biomedicines and Dr. Hood had defrauded Dr. Brewer as part of Impact Biomedicines' effort to end an FDA-mandated clinical hold and get Impact Biomedicines' experimental cancer drug approved. The jury accepted Dr. Brewer's argument that Impact Biomedicines and Dr. Hood had misled the FDA about the work Dr. Brewer had done for them and the conclusions he had reached and then concealed its false statements to the FDA from Dr. Brewer.
Later, the trial court agreed that Dr. Brewer had proven his fraud case but reduced the damages number significantly. At the time, Mr. Arledge said he disagreed with the court's decision to reduce the damages and predicted that the trial court's order would be reversed on appeal. Today it was. According to the Court of Appeal's opinion, "We conclude that substantial evidence supports the jury's findings on liability and damages, and the jury's award of punitive damages was not constitutionally excessive…"
"This was a hard-fought win against a very well-funded opponent and one of the largest, most-prestigious law firms in the country. Now a jury, a trial court, and an appellate court have all agreed that Dr. Brewer proved his fraud claim, and we're grateful to the Court of Appeal for recognizing that the trial court's reduction in Dr. Brewer's damages was a legal error," said Mr. Arledge. "This is an important win for Dr. Brewer and for patients who must be able to rely on the FDA drug-approval process."
Impact Biomedicines was represented by Colleen C. Smith, John T. Ryan, Andrew R. Gray, and Melissa Arbus Sherry, all of Latham & Watkins.
James Brewer v Impact Biomedicines, et al. Superior Court No. 37-2019-00067876-CU-CO-CTL
About Ellis George LLP
Ellis George LLP is an elite litigation and trial firm based in Los Angeles and with offices in San Francisco and New York. Whether plaintiff or defendant, individual, Fortune 500 corporation or entrepreneur, clients call upon Ellis George when seeking litigation counsel of the highest quality, creativity, dedication, and ethics. Visit www.ellisgeorge.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250721136890/en/
Contacts
Media Contact:Jim Goldman, GoldmanMediaGroup, for Ellis George LLPinfo@goldman-media-group.com 408-427-4349
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
C1 Fund Inc. Announces Pricing of Initial Public Offering
PALO ALTO, Calif., August 07, 2025--(BUSINESS WIRE)--C1 Fund Inc., a new closed-end investment company ("C1 Fund" or the "Fund"), today announced the pricing of its initial public offering of 6,000,000 shares of its common stock (the "Common Shares") at a public offering price of $10.00 per share. C1 Fund has granted the underwriters a 30-day option to purchase up to an additional 900,000 Common Shares to cover over-allotments, if any, at the public offering price less the underwriting discounts and commissions. The Common Shares are expected to begin trading on August 7, 2025, on the New York Stock Exchange under the ticker symbol "CFND." The offering is expected to close on August 8, 2025, subject to the satisfaction of customary closing conditions. The net proceeds of this offering are estimated at approximately $55.1 million (or approximately $63.4 million if the underwriters exercise their option to purchase additional Common Shares in full), after deducting underwriting discounts and commissions and the Fund's estimated offering expenses. The Fund intends to complete its investment of the net proceeds within three months, but, in any event, no later than 12 months, after the closing of the offering. The Benchmark Company, LLC is acting as sole book-running manager for the offering. SoFi Securities LLC and China Renaissance Securities (Hong Kong) Limited are acting as co-managers for the offering. A registration statement on Form N-2 (File Nos. 333-283139 and 811-24022) relating to the Common Shares has been filed with and declared effective by the U.S. Securities and Exchange Commission (the "SEC") on August 6, 2025. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained upon request to: The Benchmark Company, LLC, 150 East 58th Street, 17th Floor, New York, NY 10155, Attention: Prospectus Department, or by email at prospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer, solicitation or sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. About C1 Fund Inc. C1 Fund Inc. is a Maryland corporation based in Palo Alto, California. C1 Advisors LLC, which is also based in Palo Alto, California, will serve as the Fund's investment adviser. The Fund's investment objective is to maximize the portfolio's total return, principally by seeking capital gains on the Fund's equity and equity-related investments. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity and equity-linked securities of companies principally engaged in the digital assets services and technology sector. The Fund intends to achieve its investment objective by investing in a portfolio of what the Fund believes to be 30 of the top digital assets services and technology companies, excluding companies whose business is principally administered in the People's Republic of China, including Hong Kong and Macao. Investors should consider the Fund's investment objectives, risks, charges and expenses carefully before investing. The registration statement on Form N-2, which contains the Fund's preliminary prospectus, has been filed with the SEC, contains this information and should be read carefully before investing. Forward-Looking Statements This press release contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements relating to the offering of the Common Shares, our ability to complete the offering on the anticipated timeline or at all and the anticipated use of the net proceeds therefrom, together with other statements that are not historical facts, are forward-looking statements that are estimates reflecting management's best judgment based upon currently available information. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "confidence," "encouraged," "potential," "plan," "targets," "likely," "may," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. The forward-looking statements included in this press release are based on management's current expectations and beliefs which are subject to a number of risks, uncertainties and factors that may cause the actual results, levels of activity, performance or achievements of the Fund, or industry results, to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. As a result, no assurance can be given as to future results, levels of activity, performance or achievements, and neither the Fund nor any other person assumes responsibility for the accuracy and completeness of such statements in the future. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by these cautionary statements, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. Risk is inherent in all investing. There can be no assurance that the Fund will achieve its investment objective, and you could lose some or all of your investment. NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE View source version on Contacts For Media Enquiries contact: media@ Sign in to access your portfolio
Forbes
24 minutes ago
- Forbes
United Airlines ‘Technology Issue' Resolved, But Some Flights Still Face Delays
United Airlines on Wednesday night announced it had resolved a 'technology issue' that had triggered a ground stop for the carrier's flights at major U.S. airports earlier in the evening and triggered hundreds of delays and several dozen cancelations, although the airline was still tackling residual delays triggered by the outage. United Airlines flights were disrupted by technology issues on Wednesday night, causing hundreds of flight delays and cancelations. Copyright 2025 The Associated Press. All rights reserved Earlier on Wednesday evening, the airline told several news outlets that it was 'holding United mainline flights at their departure airports,' due to a 'technology issue,' without offering specifics. In a post on X, Transport Secretary Sean Duffy said United CEO Scott Kirby had briefed him on the matter, adding that 'the issue was specific to United's operations, and is unrelated to the broader air traffic control system.' In a notification on its website later on Wednesday night, the company said it has resolved the 'technology issues that had been affecting flights,' but noted it was still experiencing delays as its team works to restore normal operations. The Federal Aviation Administration also issued a statement saying it was aware that United 'experienced a technology issue disrupting their operations,' and noted: 'We've offered full support to help address their flight backlog.' According to FlightAware data, nearly 1100 United Airlines flights faced delays on Wednesday, which is 35% of the carrier's scheduled flights for the day. In addition to this, 157 United flights were canceled. The residual impact of the ground stop was still being felt after midnight, as 70 flights scheduled for Thursday had been canceled, while 79 had been delayed.
Medscape
25 minutes ago
- Medscape
Even Low Lead Exposure Can Impair Academic Outcomes in Kids
TOPLINE: Every 1-unit increase in blood lead levels in early childhood — even when below the 'safe' threshold of 3.5 µg/dL — was associated with declines in math and reading scores from grades 2 through 11, similar to those seen at higher lead levels. METHODOLOGY: Researchers used the 2021 US CDC's revision of the blood lead reference value to ≥ 3.5 μg/dL. They analyzed data from birth certificates of children born in Iowa from 1989 to 2010, academic test scores from grades 2 through 11, and blood lead testing data from 1990 to 2017. The analysis included 305,256 children (mean age at lead testing, 1.9 years; 49% girls) and nearly 1.8 million math and reading scores to calculate the national percentile rank (NPR). Primary outcomes included NPR scores across grades 2 through 11, comparing children with blood lead levels < 3.5 μg/dL with those at or above this threshold. TAKEAWAY: Overall, 37.7% of children had lead levels < 3.5 μg/dL. Among children with blood lead levels < 3.5 μg/dL, a 1-unit increase was associated with lower NPR scores in math (-0.47; 95% CI, -0.65 to -0.30) and in reading (-0.38; 95% CI, -0.56 to -0.20). Similarly, for lead levels at ≥ 3.5 μg/dL, every 1-unit increase was linked to a significant decline in NPR scores for math and reading. The trend of declining scores with increasing lead levels was persistent across grades 2 through 11; only the declines in reading scores for grades 10 and 11 were not statistically significant. IN PRACTICE: 'The present work provides further evidence to support that there are no safe levels of lead and that there is a need to continue to reduce or eliminate lead exposure,' the authors of the study wrote. SOURCE: This study was led by George L. Wehby, MPH, PhD, of the Department of Health Management and Policy at the University of Iowa in Iowa City, Iowa. It was published online on May 28, 2025, in JAMA Network Open. LIMITATIONS: Several laboratories used the old 5 μg/dL cutoff to quantify high lead levels. Researchers lacked data on any lead-related interventions the children may have received. DISCLOSURES: Wehby reported receiving grants from the Gates Foundation during the conduct of this study. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
